Datapoint: Incyte Scores Game-Changing Vitiligo Nod for Opzelura

The FDA last week approved Incyte’s Opzelura cream for the treatment of nonsegmental vitiligo in patients aged 12 and older, making it the first-ever repigmentation therapy for the condition. It is also the first topical JAK inhibitor to gain FDA approval, having scored an atopic dermatitis nod in September 2021. For the treatment of atopic dermatitis, 52% of all insured lives have covered or better access to Opzelura under the pharmacy benefit. Opzelura is projected to do in $115 million in worldwide sales in 2022, growing to $270 million in 2023, according to data from Evaluate Pharma.

Source: MMIT Analytics, as of 7/25/22, and Evaluate Pharma

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: United Projects 9% MA Growth in 2023

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: EmblemHealth Subsidiary Pulls Out of Connecticut Small Group Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today